Clinicians report real-life experience with NOAC reversal agent

The reversal agent for the NOAC dabigatran is proving its worth in real life emergency situations say researchers who have reported for the first time a series of case reports documenting physician and patient experience with the drug. While idarucizumab (Praxbind) has been approved for more than a year in Australia, the US and Europe, ...

Already a member?

Login to keep reading.

© 2021 the limbic